Skip to main content

Table 3 Characteristics of included studies

From: Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis

Author

Year

Number of patients

Study design

Statin

Follow-up duration

Abraldes, et al

2009

55

Randomized controlled trial

simvastatin

1 month

Kumar, et al

2014

243

Propensity Score Matching Case-control Study

atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin

13 years

Simon, et al

2015

543

Cohort study

non-selected

3.5 years

Yang, et al

2015

84,213

Propensity Score Matching Case-control Study

Non-selected

4 years

Pollo-Flores, et al

2015

34

Randomized controlled trial

simvastatin

3 months

Huang, et al

2016

13,086

Propensity Score Matching Case-control Study

non-selected

12 years

Mohanty, et al

2016

1370

Propensity Score Matching Case-control Study

atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin

14 years

Simon, et al

2016

9135

Case-control Study

atorvastatin and fluvastatin

14 years

Abraldes, et al

2016

147

Randomized controlled trial

simvastatin

2 years

Bang, et al

2017

744

Case-control Study

non-selected

8 years

Chang, et al

2017

1350

Propensity Score Matching Case-control Study

non-selected

8.5 years

Kim, et al

2017

9852

Nested Case-control Study

atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin

12 years

Wong, et al

2017

69,184

Propensity Score Matching Case-control Study

atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin

3 years

Wani, et al

2017

76

Self-control Study (Prospective Cohort)

simvastatin

3 months

Bishnu, et al

2018

23

Randomized controlled trial

atorvastatin

1 month

Kaplan, et al

2019

19,341

Propensity Score Matching Case-control Study

non-selected

5.5 years

Elwan, et al

2019

40

Randomized controlled trial

simvastatin

1 month